Skip to main content

Table 4 Neurologist network: demographic and clinical data pertaining to seven GBS patients with influenza immunisations during the 42-day period preceding clinical onset

From: Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database

Patient ref. no., sex, age Vaccination date and type (a) Co-morbidity or clinical antecedent in 30 days prior to onset Symptom onset (b) (a-b) Interval in weeks Functional level at one week Treatment Clinical confirmation on the basis of
1
Female
53
2 Oct 2009 Motor neurone disease 13 Oct 2009 1–2 Walking Not treated Clinical symptoms/exam.
2009-TIV Cerebrospinal fluid (CSF) tests
Electrophysiology lab.
Other causes excluded
2
Male
68
27 Oct 2009 Heart disease. 22 Nov 2009 3–4 Bed-bound IVGG Electrophysiology lab.
2009-TIV Sleep apnea. High blood pressure. Bronchopulmonary infection Other causes excluded
3
Male
34
20 Oct 2009 Syphilis seropositive 30 Nov 2009 5–6 Walking IVGG Clinical symptoms/exam.
2009-TIV CSF tests
Electrophysiology lab.
Other causes excluded
4
Male
70
28 Sept 2009 Motor neurone disease 10 Oct 2009 1–2 Bed-bound IVGG Clinical symptoms/exam
2009-TIV CSF tests
Electrophysiology lab.
Other causes excluded
5
Male
77
18 Oct 2010 - 1 Nov 2010 2 Bed-bound IVGG Clinical symptoms/exam.
2010–2011-TIVa Electrophysiology lab. Other causes excluded
6
Female
78
5 Jan 2011 - 15 Jan 2011 1–2 Able to walk with support IVGG Clinical symptoms/exam.
2010–2011-TIV CSF tests
Electrophysiology lab. Other causes excluded
7
Male
82
27 Oct 2011 High blood pressure 23 Nov 2011 4 Bed-bound IVGG Mechanical Ventilation Clinical symptoms/exam.
2010–2011-TIVa DM CSF tests
Atrial fibrillation Electrophysiology lab. Other causes excluded
  1. GBS Guillain-Barré syndrome, DM diabetes mellitus type 2, TIV seasonal trivalent influenza vaccine, IVGG intravenous gammaglobulin
  2. aReceived the vaccine Chiromas® (Novartis), adjuvanted with MF59C.1